Compare HUN & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUN | SRPT |
|---|---|---|
| Founded | 1970 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 2004 | 2000 |
| Metric | HUN | SRPT |
|---|---|---|
| Price | $13.69 | $21.16 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 29 |
| Target Price | $12.09 | ★ $25.85 |
| AVG Volume (30 Days) | ★ 6.1M | 3.2M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.59% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,683,000,000.00 | $2,198,237,000.00 |
| Revenue This Year | $3.04 | N/A |
| Revenue Next Year | $5.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $7.30 | $10.42 |
| 52 Week High | $14.38 | $64.80 |
| Indicator | HUN | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 60.70 | 55.46 |
| Support Level | $10.53 | $20.61 |
| Resistance Level | $14.38 | $23.51 |
| Average True Range (ATR) | 0.77 | 1.49 |
| MACD | 0.17 | 0.16 |
| Stochastic Oscillator | 94.43 | 64.90 |
Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. Its product portfolio comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, among others. Its operating segments are Polyurethanes, Performance Products, and Materials. It derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.